Drug Profile


Alternative Names: SA 3212; SD 3212

Latest Information Update: 26 Mar 2009

Price : $50

At a glance

  • Originator Santen Pharmaceutical
  • Developer Nonindustrial source; Yamanouchi
  • Class Class IV antiarrhythmics; Thiazoles; Vasodilators
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 18 May 2004 Suspended - Phase-II for Arrhythmias in Japan (PO)
  • 12 Jan 2001 No-Development-Reported for Arrhythmias in Japan (PO)
  • 18 Aug 1997 Phase-II clinical trials for Arrhythmias in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top